Merck & Co. Company Profile (NYSE:MRK)

About Merck & Co.

Merck & Co. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $62.85
  • 50 Day Moving Average: $60.63
  • 200 Day Moving Average: $55.96
  • Trailing P/E Ratio: 34.48
  • Foreward P/E Ratio: 16.37
  • P/E Growth: 2.64
  • Market Cap: $173.79B
  • Outstanding Shares: 2,765,208,000
  • Beta: 0.64
Additional Links:
Companies Related to Merck & Co.:

Analyst Ratings

Consensus Ratings for Merck & Co. (NYSE:MRK) (?)
Ratings Breakdown: 12 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.37)
Consensus Price Target: €62.81 (0.06% downside)

Analysts' Ratings History for Merck & Co. (NYSE:MRK)
DateFirmActionRatingPrice TargetDetails
8/11/2016Sanford C. BernsteinReiterated RatingOutperform$66.00 -> $74.00View Rating Details
8/10/2016Citigroup Inc.Reiterated RatingNeutral$65.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$58.00 -> $62.00View Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00View Rating Details
8/8/2016Jefferies GroupBoost Price TargetHold$53.00 -> $57.00View Rating Details
8/7/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$62.00 -> $73.00View Rating Details
8/5/2016BMO Capital MarketsUpgradeMarket Perform -> Outperform$62.00 -> $72.00View Rating Details
7/14/2016Leerink SwannReiterated RatingHold$58.00View Rating Details
6/9/2016ArgusReiterated RatingBuyView Rating Details
6/8/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$60.00View Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
5/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details
3/23/2016Morgan StanleyReiterated RatingHold$57.00View Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00View Rating Details
11/24/2015Berenberg BankInitiated CoverageHold$61.00View Rating Details
10/2/2014GuggenheimInitiated CoverageNeutral$65.00View Rating Details
(Data available from 8/26/2014 forward)


Earnings History for Merck & Co. (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Co. (NYSE:MRK)
Current Year EPS Consensus Estimate: $3.75 EPS
Next Year EPS Consensus Estimate: $3.84 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20162$0.95$0.98$0.97
Q4 20162$0.92$1.01$0.97
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Co. (NYSE:MRK)
Annual Dividend:$1.84
Dividend Yield:2.93%
Payout Ratio:101.10% (Based on Trailing 12 Months of Earnings)
49.07% (Based on Current Year Consensus EPS Estimate)
47.92% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.30% (3 Year Average)

Dividend History for Merck & Co. (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Co. (NYSE:MRK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016Clark GolestaniEVPSell3,000€63.03€189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000€61.81€24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000€58.00€3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000€57.99€2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000€57.69€2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000€57.49€1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877€54.79€2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040€56.11€7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000€55.53€277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313€55.08€2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666€54.69€1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000€54.85€274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634€60.44€642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368€60.99€2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064€60.20€3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902€59.82€9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624€59.84€5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164€58.67€302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864€58.56€7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000€58.76€293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200€62.48€4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840€62.47€552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846€60.00€590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000€62.00€3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000€59.63€596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000€59.13€295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000€57.98€579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895€59.73€591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814€60.48€593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000€59.70€1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058€57.00€573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669€56.64€1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987€58.03€579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047€59.16€10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290€58.26€4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985€58.06€579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527€55.91€588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047€57.24€575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225€56.43€8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990€55.47€332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870€55.04€2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000€55.61€1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000€55.70€557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520€54.52€2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000€54.44€272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000€54.68€2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638€48.55€2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208€46.66€1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404€46.15€249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324€44.26€2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merck & Co. (NYSE:MRK)
DateHeadline logoA Merck Versus Bristol Showdown - Seeking Alpha (NYSE:MRK) - August 26 at 6:01 PM logoInside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (ADR) (NYSE:GSK) - Market Exclusive (NYSE:MRK) - August 26 at 9:16 AM logoMerck Offers Value, Yield, And Reliable Dividends (NYSE:MRK) - August 25 at 6:13 PM logoLung cancer doctors eye Merck's Keytruda over Bristol's Opdivo (NYSE:MRK) - August 25 at 6:13 PM
News IconMarket Movers - Merck & Co (NYSE:MRK), Ballard Power Systems (NASDAQ:BLDP) - Money News (press release) (NYSE:MRK) - August 25 at 11:24 AM logoMerck Stock: MRK Preps for a Healthy Breakout | InvestorPlace - (NYSE:MRK) - August 25 at 11:24 AM logoMerck & Co., Inc. Features Slow and Steady Dividend Growth (MRK ... - (NYSE:MRK) - August 25 at 11:24 AM logoAstraZeneca’s Recent Product Developments (NYSE:MRK) - August 25 at 11:24 AM
News IconDJIA Today: Dow Futures Extend Losses as Pharmaceuticals Weigh (NYSE:MRK) - August 24 at 6:04 PM logoThe 2015 Flash Crash Was One Year Ago Today. Why Did It Happen? (NYSE:MRK) - August 24 at 6:04 PM logoMerck & Co., Inc. Features Slow and Steady Dividend Growth (MRK) (NYSE:MRK) - August 24 at 1:02 PM logoMerck & Co., Inc. (MRK) Preps for a Healthy Breakout (NYSE:MRK) - August 24 at 11:09 AM
News IconMerck & Co., Inc.'s (MRK): Shares in the Trader's Spot light - Hot Stocks Point (NYSE:MRK) - August 24 at 9:23 AM
News IconMerck & Co., Inc. (MRK): Slow And Steady Dividend Growth - ValueWalk (NYSE:MRK) - August 24 at 9:23 AM
News IconMerck Breaks To An All-Time High (NYSE:MRK) - August 23 at 10:42 AM
News IconMerck (MRK): Slow and Steady Dividend Growth (NYSE:MRK) - August 23 at 10:42 AM logoMerck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors (NYSE:MRK) - August 23 at 10:42 AM
News IconStocks in Concern on New Development: Merck & Co. (NYSE:MRK), Array BioPharma (NASDAQ:ARRY) - Street Wise Report (press release) (blog) (NYSE:MRK) - August 22 at 6:17 PM
News IconHealthcare Stocks to Track: Merck & Co., Inc. (NYSE:MRK), StemCells Inc (NASDAQ:STEM) - Post Registrar (NYSE:MRK) - August 22 at 6:17 PM
News IconMerck & Co., Inc.'s (MRK): Trend Analysis Report - Hot Stocks Point (NYSE:MRK) - August 22 at 10:51 AM
News IconDrug Manufacturers – Major: Merck & Co., Inc. (NYSE:MRK) Position of the day - Twin County News (NYSE:MRK) - August 20 at 10:21 AM
News IconAnalysts Valuations For Two Stocks: Merck & Co., Inc. (NYSE:MRK), Mondelez International Inc (NASDAQ:MDLZ) - The Voice Registrar (NYSE:MRK) - August 19 at 6:12 PM logo21.1% Return Seen to Date on SmarTrend Merck Call (MRK) (NYSE:MRK) - August 19 at 9:20 AM
News IconMerck & Co., Inc.'s (MRK): Mover to Watch - Hot Stocks Point (NYSE:MRK) - August 18 at 6:25 PM
News IconMerck & Co., Inc. (NYSE:MRK) & Nymox ... - News Is Money - Money News (press release) (NYSE:MRK) - August 18 at 6:25 PM logoMerck & Co., Inc. (NYSE:MRK)'s MSD Selling Primary Care Drugs ... - Market Exclusive (NYSE:MRK) - August 18 at 6:25 PM logoIs Valeant’s Xifaxan Resuming Growth? (NYSE:MRK) - August 17 at 9:22 AM logoMerck cutting 148 Montco jobs (NYSE:MRK) - August 16 at 6:24 PM
News IconMerck cuts 148 jobs after giving up on ex-blockbuster hopeful Zontivity (NYSE:MRK) - August 16 at 6:24 PM logoWhy Gardasil Is So Important to Merck’s Vaccines Business (NYSE:MRK) - August 16 at 9:35 AM
News IconAnalysts Valuations For Two Stocks: Merck & Co., Inc. (NYSE:MRK), American Airlines Group Inc (NASDAQ:AAL) - The Voice Registrar (NYSE:MRK) - August 15 at 8:29 AM
News IconUtah Retirement Systems Lowers stake in Merck & Co. (MRK) (NYSE:MRK) - August 13 at 6:00 PM logoMERCK & CO., INC. Financials (NYSE:MRK) - August 13 at 6:00 PM
News IconMerck not only loses hep C case against Gilead, it gets stuck with the bill (NYSE:MRK) - August 12 at 6:21 PM logoYieldBoost Merck & Co. From 2.9% To 4.7% Using Options (NYSE:MRK) - August 12 at 6:21 PM logoHow Did Merck’s Animal Health Segment Perform? (NYSE:MRK) - August 12 at 6:21 PM logoWhat’s Contributing to Merck’s Growth? (NYSE:MRK) - August 12 at 6:21 PM
News IconBrokerage Recom. Worth Watching: Merck & Co., Inc. (NYSE:MRK) - The Voice Registrar (NYSE:MRK) - August 11 at 9:27 AM
News IconMerck & Co., Inc. (NYSE:MRK) & AMETEK, Inc. (NYSE:AME) Traders Recap - Money News (press release) (NYSE:MRK) - August 10 at 6:41 PM
News IconMerck & Co. (NYSE: MRK) Price Target Increased at Deutsche Bank AG - BNB Daily (blog) (NYSE:MRK) - August 10 at 6:41 PM
News IconHC Stocks Analysis: Endo International plc (ENDP), Merck & Co., Inc. (MRK) - share market updates (press release) (NYSE:MRK) - August 10 at 6:41 PM logoOne Put, One Call Option To Know About for Merck & Co. (NYSE:MRK) - August 10 at 9:21 AM logoMMM Becomes #11 Most Shorted Dow Stock, Replacing Merck (NYSE:MRK) - August 10 at 9:21 AM logoMerck & Company Inc. (new) (MRK) is Trading Lower on Unusual Volume for August 08 (NYSE:MRK) - August 10 at 9:21 AM logoMajor Pharma Short Interest Slides (NYSE:MRK) - August 10 at 9:21 AM logoAn Update on Analyst Recommendations for Novo (NYSE:MRK) - August 10 at 9:21 AM logoDow Movers: MRK, GS (NYSE:MRK) - August 9 at 6:31 PM logoMerck & Company Inc. (new) (MRK) Closes 0.59% Down on the Day for August 09 (NYSE:MRK) - August 9 at 6:31 PM logoMerck (MRK) Announces Publication of Strong ZEPATIER Phase 3 Data as HCV Treatment (NYSE:MRK) - August 9 at 9:27 AM logoBecker Capital Management Inc Lowers stake in Merck & Co. (MRK) (NYSE:MRK) - August 9 at 9:27 AM


Merck & Co. (NYSE:MRK) Chart for Friday, August, 26, 2016

Last Updated on 8/26/2016 by Staff